Market Size of Thrombosis Drugs Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 9.00 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Thrombosis Drugs Market Analysis
The thrombosis drugs market is expected to register a CAGR of about 9.0% over the forecast period.
The COVID-19 pandemic had a significant impact on the studied market growth. For instance, according to the World Health Organization, 2021, services for cardiovascular crises have been interrupted partially or entirely in more than half of the nations examined during the early pandemic. Furthermore, according to the study published in the British Medical Journal in December 2021, in individuals with COVID-19, antiplatelet therapy (APT) may help reduce mortality; a randomized experiment (RECOVERY) found that aspirin therapy is linked to a 1.2% absolute gain in survival. Thus, the COVID-19 outbreak affected the market's growth significantly; however, as the pandemic has currently subsided, the market is expected to experience pre-pandemic growth levels during the study's forecast period.
The market is primarily driven by the increase in the geriatric and obese population, the rising burden of cardiovascular diseases and trauma cases, and the technological advancement in haematology. For instance, according to the United Nations World Population Prospects 2022, the share of the global population aged 65 years or above is projected to rise from 10 per cent in the current year to 16 per cent in 27 years. The source also stated that by 2050, the number of persons aged 65 years or over worldwide is projected to be more than twice the number of children under age five and about the same as that of children under age 12. Since the older population is prone to the disease, it is expected to generate the need for these drugs for treatment, thereby driving the market's growth.
Additionally, the increasing burden of obesity has also changed significantly in the last decade globally. Developed and emerging markets are having significant issues controlling the associated diseases. The growing consumption of alcohol and tobacco, with overweight and obesity, adds a high risk of developing significant blood pressure in veins for a long period of life, leading to several thrombosis-related complications, thus driving this market. For instance, according to the World Health Organization Report of March 2022, globally, over 1 billion individuals, including 650 million adults, 340 million teenagers, and 39 million children, were obese in 2022. Additionally, 167 million adults and children are expected to have worse health in two years due to being overweight or obese. Thus, with the increase in the obese population, the demand for thrombotic drugs is expected to increase over the forecast period as obesity is a significant cause of vascular diseases. Other factors contributing to the growth of this market are increasing the burden of cardiovascular and trauma cases, and the increasing research and development expenditure in the field of hematological disorders.
However, a lack of awareness about venous thromboembolism conditions and the side effect associated with thrombosis drugs may restrain the market growth over the forecast period.
